Fujisawa Healthcare, Inc.

Positive results reported in comparative Prograf trial

Published in Surgery Litigation and Law Weekly, June 18th, 2004

Results of a phase II (dosing regimen) study in stable liver transplant recipients presented at the 5th American Transplant Congress show that a standard regimen of Prograf (tacrolimus), administered twice daily, and the Modified Release (MR) tacrolimus, administered once daily, have similar drug exposure, as measured by blood levels, and the conversions were safe and well-tolerated.

MR tacrolimus is an extended release version of the original Prograf formulation.

Immediately following transplant surgery, patients are prescribed and expected to manage a multitude of daily medications, including an anti-rejection regimen that consists of several...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly

Source: Surgery Litigation and Law Weekly (2004-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry